Brokerages predict that aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) will report earnings per share of ($0.44) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for aTyr Pharma’s earnings. The highest EPS estimate is ($0.36) and the lowest is ($0.48). aTyr Pharma reported earnings per share of ($0.64) in the same quarter last year, which would suggest a positive year-over-year growth rate of 31.3%. The firm is expected to announce its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that aTyr Pharma will report full-year earnings of ($1.78) per share for the current financial year, with EPS estimates ranging from ($1.93) to ($1.54). For the next year, analysts forecast that the business will report earnings of ($1.88) per share, with EPS estimates ranging from ($2.50) to ($1.15). Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that that provide coverage for aTyr Pharma.
aTyr Pharma (NASDAQ:LIFE – Get Rating) last issued its earnings results on Monday, May 9th. The biotechnology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.10). During the same period in the prior year, the business posted ($0.51) earnings per share.
Shares of NASDAQ LIFE remained flat at $$3.00 during mid-day trading on Friday. The company had a trading volume of 79,316 shares, compared to its average volume of 90,696. aTyr Pharma has a 1-year low of $2.89 and a 1-year high of $13.10. The firm’s 50 day simple moving average is $4.56 and its 200 day simple moving average is $6.04. The firm has a market cap of $84.18 million, a PE ratio of -1.66 and a beta of 1.54.
Large investors have recently modified their holdings of the stock. VR Adviser LLC acquired a new stake in shares of aTyr Pharma during the 3rd quarter worth approximately $14,210,000. Tikvah Management LLC grew its stake in shares of aTyr Pharma by 10.2% during the 1st quarter. Tikvah Management LLC now owns 1,350,833 shares of the biotechnology company’s stock worth $7,227,000 after purchasing an additional 125,000 shares during the period. Vanguard Group Inc. grew its stake in shares of aTyr Pharma by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 1,139,533 shares of the biotechnology company’s stock worth $6,097,000 after purchasing an additional 26,342 shares during the period. Tang Capital Management LLC acquired a new stake in shares of aTyr Pharma during the 3rd quarter worth approximately $10,110,000. Finally, Deep Track Capital LP acquired a new stake in shares of aTyr Pharma during the 4th quarter worth approximately $8,217,000. Institutional investors own 77.96% of the company’s stock.
About aTyr Pharma (Get Rating)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
- Get a free copy of the StockNews.com research report on aTyr Pharma (LIFE)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.